HCC
SPPI

Hirtle Callaghan & Co’s Spectrum Pharmaceuticals Inc SPPI Stock Holding History

Hirtle Callaghan & Co’s Portfolio SPPI Stock Details SPPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-300
Closed -$3K – 658
2013
Q3 		$3K Buy
+300
New +$2.43K ﹤0.01% 540

Other funds holding SPPI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FCAM
F&C Asset Management Edinburgh, Scotland, United Kingdom $7.92B AUM 24.35% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Hirtle Callaghan & Co's SPPI Position: Q4 2013 in Review

Hirtle Callaghan & Co sold out of Spectrum Pharmaceuticals Inc (SPPI) in Q4 2013, closing a stake of 300 shares — an estimated $3K sold.

Hirtle Callaghan & Co first reported a position in SPPI in Q3 2013 and held it in 1 quarter. The position peaked at $3K in Q3 2013. 115 funds tracked by Wall St. Rank hold SPPI as of Q4 2013.

  • Hirtle Callaghan & Co reported no remaining Spectrum Pharmaceuticals Inc position as of Q4 2013 after selling out during the quarter.
  • Hirtle Callaghan & Co sold 300 Spectrum Pharmaceuticals Inc shares in Q4 2013, an estimated $3K.
  • Hirtle Callaghan & Co first reported a position in Spectrum Pharmaceuticals Inc in Q3 2013 and held it in 1 quarter.
  • Hirtle Callaghan & Co's Spectrum Pharmaceuticals Inc position peaked at $3K in Q3 2013.
  • 115 funds tracked by Wall St. Rank held Spectrum Pharmaceuticals Inc as of Q4 2013.

Based on Hirtle Callaghan & Co's 13F filing for Q4 2013, filed 29 Jan 2014.